How much cash does Insight Molecular Diagnostics Inc. Common Stock generate?

Insight Molecular Diagnostics Inc. Common Stock (IMDX) generated -$24.0M in operating cash flow over the trailing twelve months.

What is Insight Molecular Diagnostics Inc. Common Stock's free cash flow?

After $3.5M of capital expenditures, Insight Molecular Diagnostics Inc. Common Stock's free cash flow was -$27.5M over the trailing twelve months, down 16.9% year over year.

Where does Insight Molecular Diagnostics Inc. Common Stock's cash flow data come from?

Every line is extracted from Insight Molecular Diagnostics Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Insight Molecular Diagnostics Inc. Common Stock IMDX Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Net income	-$50.22M+17.2%	-$60.66M-118%	-$27.78M+61.9%	-$72.9M-13.7%
Depreciation and amortization	$2.19M+48.4%	$1.48M-7.3%	$1.59M+4.2%	$1.53M+81.0%
Stock-based compensation	$2.22M+26.6%	$1.75M-36.5%	$2.76M-72.5%	$10.04M+46.8%
Change in accounts receivable	——	$1.13M—	——	——
Change in inventories	——	$410K—	——	——
Change in accounts payable	$2.65M+174%	$967K+120%	-$4.88M—	——
Change in other assets	——	$442K+153%	-$836K—	——
Amortization of intangible assets	$14.6M-65.2%	$41.9M—	——	$3.69M+9.8%
Change in operating lease liabilities	-$142K+51.2%	-$291K—	——	——
Change in fair value of contingent consideration	——	-$4.28M—	——	-$31.02M-214%
Net cash from operating activities	-$22.18M-7.2%	-$20.69M+11.3%	-$23.33M+48.8%	-$45.57M-26.8%
Capital expenditures	$3.19M+517%	$516K—	——	$4.34M+93.1%
Net cash from investing activities	-$3.19M-522%	-$512K—	——	-$4.34M+68.9%
Proceeds from issuance of common stock	——	$26.01M+87.8%	$13.85M-57.8%	$32.81M—
Taxes paid for net share settlement	$72K—	$0—	——	——
Other financing activities	$2K—	$0—	——	——
Net cash from financing activities	——	$20.68M—	——	——
Effect of exchange rate changes on cash	——	——	——	——
Net increase (decrease) in cash	——	——	——	-$14.1M—
Interest paid	$91K+117%	$42K+500%	$7K-70.8%	$24K-78.9%
Income taxes paid	$0—	$0—	——	——
Amortization of capitalized software and acquired intangible assets	$7K-92.0%	$88K0.0%	$88K-97.6%	$3.69M+9.8%
Contingent consideration fair value adjustments	——	-$4.28M—	——	-$31.02M-214%
Equity Compensation For Bonus Awards And Consulting Services	$164K—	——	——	——
Unrealized Gain (Loss), Foreign Currency Transaction, before Tax	——	——	——	——
Operating lease liabilities	-$142K+51.2%	-$291K—	——	——
Increase (Decrease) in Prepaid Expense and Other Assets	——	$442K+153%	-$836K—	——
Payments Of Stock Issuance Costs	——	$1.37M+222%	$427K+9.8%	$389K—
Repayment Of Financing Lease Obligations	$510K—	——	——	——
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations	——	——	——	——
Financing Costs To Issue Common Shares Included In Accounts Payable And Accrued Liabilities	——	——	——	——
Increase Decrease In Operating Lease Liability	-$142K+51.2%	-$291K—	——	——
Accrued payables for stock repurchases, including applicable excise tax	$1.14M-36.6%	$1.79M—	——	——
Machinery And Equipment Purchases And Construction In Progress Included In Accounts Payable And Accrued Liabilities	——	——	——	——
Payment For Contingent Consideration Liability Financing Activities	$2K—	$0—	——	——
Income Taxes Paid, Net	$0—	$0—	——	——
Free cash flow	-$25.37M-19.6%	-$21.21M—	——	-$49.91M-30.7%
Free cash flow	-$25.37M-19.6%	-$21.21M—	——	-$49.91M-30.7%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Insight Molecular Diagnostics Inc. Common Stock.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

How much cash does Insight Molecular Diagnostics Inc. Common Stock generate?: Insight Molecular Diagnostics Inc. Common Stock (IMDX) generated -$24.0M in operating cash flow over the trailing twelve months.
What is Insight Molecular Diagnostics Inc. Common Stock's free cash flow?: After $3.5M of capital expenditures, Insight Molecular Diagnostics Inc. Common Stock's free cash flow was -$27.5M over the trailing twelve months, down 16.9% year over year.
Where does Insight Molecular Diagnostics Inc. Common Stock's cash flow data come from?: Every line is extracted from Insight Molecular Diagnostics Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.